In this edition:
Pembrolizumab + chemo for cervical cancer
Tisotumab vedotin + pembrolizumab in r/mCC
Adavosertib in recurrent HGSC
Olaparib and OS in PSROC
Rucaparib vs placebo in ovarian cancer
Cytoreductive surgery for 2nd ovarian cancer relapse
Safety and efficacy of MORAb-202 for PRSOC
Impact of ONA-XR on PR+ GCT, LGSOC, EEC cancer
Neoadjuvant fulvestrant + abemaciclib for LGSOC
Implications of tbNGS in ovarian cancer
Please login below to download this issue (PDF)